0.9827
price down icon3.66%   -0.0373
 
loading
전일 마감가:
$1.02
열려 있는:
$1.02
하루 거래량:
106.27K
Relative Volume:
0.30
시가총액:
$6.48M
수익:
-
순이익/손실:
$-5.85M
주가수익비율:
-0.1469
EPS:
-6.6877
순현금흐름:
$-8.00M
1주 성능:
-7.29%
1개월 성능:
+35.54%
6개월 성능:
-40.80%
1년 성능:
-89.08%
1일 변동 폭
Value
$0.94
$1.05
1주일 범위
Value
$0.94
$1.05
52주 변동 폭
Value
$0.6427
$15.06

Alzamend Neuro Inc Stock (ALZN) Company Profile

Name
명칭
Alzamend Neuro Inc
Name
전화
844-722-6333
Name
주소
3500 LENOX RD. NE, ATLANTA
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-09-12
Name
최신 SEC 제출 서류
Name
ALZN's Discussions on Twitter

ALZN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ALZN
Alzamend Neuro Inc
0.9827 6.48M 0 -5.85M -8.00M -6.6877
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-10-01 개시 Ascendiant Capital Markets Buy

Alzamend Neuro Inc 주식(ALZN)의 최신 뉴스

pulisher
Mar 30, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey

Mar 28, 2025
pulisher
Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India

Mar 27, 2025
pulisher
Mar 26, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com

Mar 24, 2025
pulisher
Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 20, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 19, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan

Mar 18, 2025
pulisher
Mar 17, 2025

Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 15, 2025

Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com

Mar 14, 2025
pulisher
Mar 13, 2025

Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace

Mar 11, 2025
pulisher
Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga

Mar 11, 2025
pulisher
Mar 10, 2025

Alzamend Neuro Inc. (ALZN) reports earnings - Quartz

Mar 10, 2025
pulisher
Mar 05, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Alzamend Neuro announces initiation date of Phase II trial of AL001 - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Alzamend Neuro Announces Phase II Clinical Study of AL001 for Bipolar Disorder Expected to Start in Q3 2025 - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Alzamend Neuro Plans Phase II Trial for Advanced Lithium Treatment in Bipolar Disorder | ALZN Stock News - StockTitan

Mar 04, 2025
pulisher
Mar 03, 2025

Alzamend Neuro Announces Bylaws Amendment and New Stock Series By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Alzamend Neuro Announces Bylaws Amendment and New Stock Series - Investing.com

Mar 03, 2025
pulisher
Mar 01, 2025

Alzamend Neuro stock hits 52-week low at $0.81 amid sharp decline - Investing.com Australia

Mar 01, 2025
pulisher
Feb 28, 2025

Alzamend Neuro inks deal for equity securities sale By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Alzamend Neuro inks deal for equity securities sale - Investing.com

Feb 28, 2025

Alzamend Neuro Inc (ALZN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):